Assertio Holdings, Inc.
assertiotx.comWhat Do They Do?
Markets prescription medicines for oncology care, seizures, and pain-related conditions to wholesale distributors and specialty pharmacies.
10-K for FY2025, filed Mar 16, 2026We are a pharmaceutical company with comprehensive commercial capabilities offering differentiated products designed to address patients’…View ↗
We have built our product portfolio through the acquisition or licensing of approved products, including our lead product, ROLVEDON, which…View ↗
A benzodiazepine indicated for the adjunctive treatment of seizures associated with Lennox-Gastaut Syndrome (“LGS”) in patients aged two…View ↗
A prescription NSAID indicated in adult patients for the short-term (up to five days) management of moderate to moderately severe pain that…View ↗
A prescription NSAID indicated for the acute treatment of migraine attacks with or without aura in adults 18 years of age or older. CAMBIA…View ↗
We sell our products to our customers noted in the table above, who are primarily wholesalers. These wholesalers, in turn, sell our…View ↗
How Do They Make Money?
Assertio sells medicines to distributors and specialty pharmacies, with receivables typically collected one to two months after delivery; it also earns royalties under a Canadian CAMBIA license.
10-K for FY2025, filed Mar 16, 2026
$118.7M
-
10-K for FY2025, filed Mar 17, 2026
$118.7M ↗
| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Product sales, net
Sold outright
10-K for FY2025, filed Mar 16, 2026 |
99%
FY2022: 99%
|
Product sales, net, FY2025
$117.1M Sources
|
Sold outright |
|
Royalty revenue
Licensed
|
1.4% |
Royalty revenue, FY2025
$1.6M Sources
|
Licensed |
|
Other revenue
|
0.0%
FY2022: −0.8%
|
Other revenue, FY2025
$0 Sources
|
Who Are Their Customers?
The company sells primarily to national wholesale distributors, which resell products to hospitals, outpatient clinics, and pharmacies; it generally does not sell directly to those end users, but its sales force works with them and health professionals to generate demand.
10-K for FY2025, filed Mar 16, 2026
10-K for FY2025, filed Mar 16, 2026
Consolidated revenue Accounts receivable related to product sales Year ended December 31, As of December 31, 2025 2024 2025 2024 Cencora 45…View ↗
Do Revenues Turn Into Profits?
No. It lost $30.4M in FY2025.
10-K for FY2025, filed Mar 17, 2026
How Are They Changing?
- Net income
-
Sources
10-Q for Q1 FY2026, filed May 9, 2026
−$18.9MView ↗
- ▲ +39% (Loss)
- vs −$13.5M in Q1 FY2025
10-Q for Q1 FY2026, filed May 8, 2026
Open tableView ↗
-
Jun 16, 2026
Zydus completed its acquisition of Assertio, which became a wholly owned subsidiary.
Assertio shares were delisted from Nasdaq, and stockholders received $23.50 per share in cash.
Sources
8-K, filed Jun 16, 2026
LAKE FOREST, IL, June 16, 2026 – Assertio Holdings, Inc. (Nasdaq: ASRT) (“Assertio” or the “Company”) today announced the successful…View ↗
Flat. Revenue was $118.7M in FY2025, about the same as the $111M of FY2021.
Oncology focus
The earlier portfolio focused on neurology, rheumatology, and pain and inflammation; the latest report centers marketing on oncology and identifies ROLVEDON as its lead product.
10-K for FY2022, filed Mar 8, 2023 10-K for FY2025, filed Mar 16, 2026We are a commercial pharmaceutical company offering differentiated products to patients utilizing a non-personal promotional model. Our…View ↗
Otrexup exit Otrexup was listed among marketed products in the earlier report, but the latest report says Assertio ceased its commercialization.
Loading...
